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Hyperkalemic solutions that are used as cardioplegic agents, while effective in 
inducing electromechanical arrest, are only partially cardioprotective, and 
ventricular dysfunction has been observed. The underlying pathophysiology of 
cardioplegia-associated v ntricular dysfunction is complex and not fully un- 
derstood, but it could be related, in part, to intracellular Ca 2+ loading induced 
by high K + concentrations present in cardioplegic solutions. Yet no effective 
cytoprotective means against possible intracellular Ca 2+ loading, under these 
conditions, has been described. Recently, potassium channel openers, which 
open adenosine triphosphate-sensitive K s channels, have been reported to 
possess cardioprotective properties under global ischemic onditions. How- 
ever, it is not known whether these novel agents could prevent intracellular 
Ca 2+ loading that could occur during cardioplegia. Intracellular Ca 2÷ was 
monitored in ventricular myocytes, loaded with the Ca2+-sensitive fluorescent 
probe Fluo-3AM, using epifluorescent digital imaging and laser confocal 
microscopy. Exposure of a myocyte to a 16 mmol/L concentration of K +, a 
concentration of K s commonly used in cardioplegic solutions, induced a 
nonhomogeneous increase in intracellular Ca 2+. Potassium channel opening 
drugs, such as aprikalim or nicorandil, effectively prevented these solutions 
from increasing intracellular Ca 2÷. The preventive effect of potassium channel 
opening drugs was antagonized by glyburide, a selective blocker of adenosine 
triphosphate-sensitive K s channels. This study demonstrates, at the single 
cardiac ell level, that solutions containing a 16 mmol/L concentration ofK + 
promote intracellular Ca 2+loading, which can be prevented by potassium 
channel opening drugs. Therefore, potassium channel opening drugs should be 
considered to prevent intracellular Ca 2+ loading associated with the use of 
cardioplegic solutions. (J Thorac Cardiovasc Surg 1996;112:820-31) 
C ardioplegic solutions that contain high concen- 
trations of K + have been used to achieve cardiac 
arrest and to protect he myocardium during cardio- 
pulmonary bypass operations, z' 2 Although effective 
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in inducing electromechanical rrest, cardioplegic 
solutions are only partially cardioprotective against 
global surgical ischemia. 3-5 Despite various modifi- 
cations implemented in hyperkalemic ardioplegic 
solutions, ventricular dysfunction is common and 
still contributes to the morbidity and mortality asso- 
ciated with cardiac surgery. 6-8 
The pathophysiology underlying cardioplegia- 
related ventricular dysfunction is complex and, at 
present, not fully understood. 6-8 However, myocar- 
dial cytosolic Ca 2-- accumulation has been observed 
after a cardioplegic hallenge and could play a role 
in the development of ventricular dysfunction. 9' 10 
The cellular mechanism of Ca 2+ accumulation has 
been related, in part, to the high K + concentration 
present in conventional cardioplegic solutions. 9 
Neither the spatial distribution of intracellular 
Ca z+ changes induced by high K+-containing solu- 
tions nor effective cytoprotection against intracellu- 
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lar Ca a÷ loading has been defined in cardiac cells. 
Recently, potassium channel openers, which acti- 
vate K + channels sensitive to adenosine triphos- 
phate (ATP), have been shown to be cardioprotec- 
tive during ischemic insults and may improve 
myocardial protection during global surgical isch- 
emia. 11 However, it is not known whether potassium 
channel openers are capable of protecting cardiac 
cells from Ca 2+ loading during a high K ÷ cardiople- 
gic challenge. 
The aims of the present study were as follows: (1) 
to determine intracellular Ca a÷ changes in single 
cardiac cells exposed to high K ÷ solutions; (2) to 
examine whether two currently used strategies to 
minimize myocardial injury, namely removing extra- 
cellular Ca 2+ or adding extracellular Mg2+, 12-14 
affect intracellular Ca a+ level in cardiac cells ex- 
posed to high K ÷ solutions; and (3) to evaluate 
whether drugs that open potassium channels protect 
ventricular myocytes from intracellular Ca a+ 
changes induced by high K + solutions. 
Methods 
Cell isolation. Ventricular myocytes were isolated from 
guinea pig hearts by enzymatic dissociation. 15 In the 
pentobarbital nesthetized and artificially ventilated ani- 
mal, the aorta was rapidly cannulated and the heart 
retrogradely perfused through the coronary arteries at 
37°C with the following solution: (1) normal Tyrode 
solution for 5 minutes to remove the blood, (2) nominally 
Ca2+-free solution for 5 minutes to cleave desmosomal 
and intermediate junctions, (3) nominally Ca2+-free solu- 
tion containing collagenase (0.04 gin/100 ml Sigma type I, 
Sigma Chemical Company, St. Louis, Mo.) for 45 minutes 
to disrupt extracellular matrix, and (4) high K+-low C1 
solution for 5 minutes to remove the collagenase and 
provide high-energy substrate to the partially digested 
myocardium. So that loosened myocytes could be re- 
leased, a small piece of the collagenase-treated v ntricle 
was dissected and agitated in dishes filled with Tyrode 
solution in which cells then rested. Isolated cardiac myo- 
cytes were used because they are a pure myocardial 
preparation with no neuronal or vascular elements, and 
the response of isolated cells is not affected by diffusion 
barriers between the surface and the core of the muscle or 
by changes in preload, afterload, or coronary flow. The 
experimental protocol was approved by the Institutional 
Animal Care and Use Committee at the Mayo Clinic (No 
A33-94). 
Flnorescent probes. The Ca2+-selective fluorescent 
probe Fluo-3 acetoxymethylester (Fluo-3AM) was used to 
monitor relative changes in Ca 2+ concentration. This 
probe exhibits lower binding capacity for Ca 2÷ and pro- 
duces larger fluorescence signals after Ca 2+ binding than 
conventional f uorescent probes. 16 Aliquots of 50 /~g of 
Fluo-3AM were dissolved in 50 t~l of dimethyl sulphoxide 
(DMSO) plus 6 /xl of a 25% solution of pluronic acid. 
Ventricular myocytes were loaded for 45 to 60 minutes, at 
room temperature with Fluo-3AM (10 txmol/L). Then 
they were transferred to a coverlip mounted on the 
perforated bottom of an experimental chamber placed on 
the stage of an inverted epifluorescent or confocal micro- 
scope and superfused with Tyrode solution. Fluorescent 
measurements were carried out at room temperature 
(23 ° C). In a separate set of experiments, cardiomyocytes 
were loaded with the ratiometric dye Fura-2 acetoxyl- 
methylester (Fura-2AM; 10 /xmol/L) to quantify resting 
intracellular Ca 2+ concentration. 17 
Epifluorescent digital microscopy. Rod-shaped ven- 
tricular myocytes with clear striation were imaged by 
digital epifluorescent microscopy by means of an inverted 
microscope (Zeiss Axiovert-135 TV, Cad Zeiss, Inc., 
Thornwood, N.Y.) with a 40× oil-immersion objective 
lens. Optimal focus was adjusted by viewing myocytes 
under bright field microscopy. A 100 W mercury lamp 
served as a source of light to excite Fluo-3AM at 488 nm 
(or Fura-2AM at 340 and 380 nm). Fluorescence emitted 
at 520 nm by the "excited" dyes was captured, after 
crossing a dichroic mirror, by an intensified charge-cou- 
pled device camera nd digitized using the epifluorescent 
imaging system (Attoflor RatioVision, Atto Instruments, 
Inc., Rockville, Md.). Background fluorescence (Tyrode 
solution containing no cells) was subtracted from the 
fluorescence of Fluo-3AM (or Fura-2AM)-loaded myo- 
cytes. 
Laser confocal microscopy. Confocal aser microscopy 
has made possible the precise spatial characterization f 
changes in intracellular Ca e÷. This technique permits the 
optical slicing of myocytes in planes as thin as 500 nm. 
Fluo-3AM-loaded ventricular myocytes were imaged with 
a Zeiss LSM-410 laser-scanning confocal microscope us- 
ing the 488 nm line of an argon/krypton laser. An excita- 
tion dichroic mirror with a cutoff of 510 nm and a 
long-pass emission filter with a cutoff of 520 nm were used 
to detect Fluo-3AM fluorescence using a photomultiplier 
tube. Scanning optics scanned the excitation light over a 
sample in a raster fashion, building the image pixel by 
pixel. Two-dimensional confocal images were acquired by 
scanning an image of 100 × 100 pixels at the highest 
possible rate that still resulted in sufficient signal to noise. 
This procedure resulted in an image-acquisition rate of 
about 4 frames per second. Cells with detectable motion 
artifacts were excluded from the study. Sequences of 
digitized images were transferred to an SGI Indigo 2 
Extreme workstation (Silicon Graphics, Mountain View, 
Calif.) for off-line analysis by the ANALYZE image 
analysis ystem developed at the Mayo Clinic. 
Calibration of the Fura-2 and Fluo-3 signals. In cells 
loaded with Fura-2AM, an estimate of the Ca 2+ concen- 
tration ([Ca2+]) was obtained according to the equa- 
tion17, 18. 
i - emi  n 
[Ca2+] = Rm~ ~ Kd[3 
• where R is the fluorescence ratio recorded from the cell 
and Rm~n and Rm~x represent the fluorescence ratio in the 
absence of Ca a÷ (extracellular Ca 2+ was removed and a 3 
mmol/L concentration of ethylene glycol-bis(/3-amino- 
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ethyl ether)N,N,N',N'-tetraacetic acid [EGTA] added to 
the extracellular solution) and at high Ca 2÷ concentration 
(CaC12 3 mmol/L), respectively. Ka is the Ca 2+ dissocia- 
tion constant of the dye (236 nmol/L), and t3 the ratio of 
minimum to maximum fluorescence at 380 nm. 17' 18 So 
that Rmin and Rm~, could be obtained, Fura-2AM-loaded 
cardiac cells were exposed to the calcium ionophore 
4-bromo A-23187. So that contraction of permealized 
cells exposed to high concentrations of extracellular 
Ca 2÷ could be prevented, myocytes were pretreated with 
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (2 
Ixmol/L) and 2,3-butaneodione monoxime (40 mmol/L). 
The intracellular Ca 2+ concentration i  quiescent ventric- 
ular myocytes estimated from Fura-2 AM-loaded cells 
was 81 + 10 nmol/L (n = 21). 
The increase in intracellular Ca 2+ concentration as a 
function of Fluo-3 fluorescence was estimated by resolving 
the system of three equations, which include the expres- 
sion for equilibrium Ca 2÷ concentration using the relative 
fraction of bound (fca) and unbound (f,) Fluo-3 to Ca:+: 
[Ca2+] _ fCa : F~ (1) 
where K d is dissociation constant of Fluo-3 (422 nmol/L) 
and fCa and f ,  relate to the total concentration of Fluo-3 
by the relation: 
fc~ +f~ =ft (2) 
The relation between Fluo-3 intensity (F) and the above 
parameters is given by: 
_fca L 
F = l~mo~ + Fminf (3) 
J, J, 
where Fm~x and Fmi. are the maximum and minimum 
Fluo-3 fluorescence intensity. Resolving equations 1, 2, 
and 3 relatively to Ca 2+ concentration produces the 
following equation: 
F - Fmi n 
[Ca2+] = gcl Fm~ x - F 
The estimate of cytosolic Ca 2+ concentration is calcu- 
lated taking into account he resting cytosolic Ca 2÷ con- 
centration.19 
Solutions and drugs. Tyrode solution had the following 
composition (in millimoles per liter) NaC1, 136.5; KC1, 
5.4; CaCI2, 1.8; MgCI2, 0.53; glucose, 5.5; and HEPES- 
NaOH, 5.5 (pH 7.4). High K+/low CI- contained (in 
millimoles per liter) taurine, 10; oxalic acid, 10; glutamic 
acid, 70; KC1, 25; KU2PO4, 10; glucose, 11; EGTA, 0.5; 
and HEPES-KOH, 10 (pH 7.4). Hyperkalemic solutions 
were prepared by adding K + in a concentration of 10.6 
mmol/L to the Tyrode solution (final K ÷ concentration: 
16 retool/L). Hyperkalemic nominally Ca2÷-free solution 
had the same composition as the hyperkalemic Tyrode 
solution with the exception that Ca 2+ was omitted. Solu- 
tions containing a 16 mmol/L concentration of MgC12 
were prepared by adding MgC12 (15.5 mmol/L) to the 
Tyrode solution. Aprikalim, nicorandil, and glyburide 
were dissolved in HC1 (1N), water, and DMSO, respec- 
tively, as concentrated stock solutions. All drugs were 
diluted to their final concentrations in the control Tyrode 
solution immediately before the experiment. Cardiomyo- 
cytes were incubated in Tyrode solution supplemented 
with aprikalim alone, nicorandil alone, or glyburide plus 
aprikalim for at least 10 minutes before the addition of a 
hyperkalemic challenge. 
Statistics. Results are expressed as means _+ standard 
error. Significance was determined by Student's t test, and 
p < 0.05 was considered significant. 
Results 
Hyperkalemic solutions increase intracellular 
Ca 2+ concentration in cardiomyocytes. Exposure of 
a single ventricular myocyte to a 16 mmol/L concen- 
tration of K +, a concentration present in commonly 
used cardioplegic solutions (e.g., St. Thomas' Hos- 
pital solutionS), induced an increase in intracellular 
Ca 2+ concentration (Fig. 1, A). Before addition of 
high K+-containing solution, intracellular Ca 2+ 
concentration was estimated at 133 _ 7 nmol/L (n = 
74; Fig. 1, B), a value that is within the range for 
intracellular Ca 2+ concentration measured during 
diastole. 2°-22 On addition of a 16 mmol/L dose of 
K +, intracellular Ca 2+ concentration increased to 
an estimated peak value of 441 _ 32 nmol/L (n = 
20;p < 0.0001; Fig. 1, B). Thus a 16 mmol/L dose of 
K + induced a 3.3-fold increase in intracellular Ca 2+ 
concentration as visualized by epifluorescent mi- 
croscopy in single cardiac cells. 
The elevation in intracellular Ca 2+ concentration 
was abrupt after the 16 mmol/L K + challenge, and 
maximal increases in intracellular Ca 2+ concentra- 
tion were reached within 15 to 20 seconds (Fig. 2, 
B). Elevation in intracellular Ca 2+ concentration i
the majority of cells was sustained at the peak level 
for more than 10 minutes. In some myocytes, intra- 
cellular Ca 2+ concentration gradually declined from 
its peak value but remained above baseline (Fig. 2, 
B). Thus solutions containing K + concentrations of
16 mmol/L increase intracellular Ca 2+ concentra- 
tion above diastolic levels for a prolonged period. 
Within a myocyte, high K+-  containing solutions 
induced an apparently nonhomogeneous spatial dis- 
tribution of Ca 2+, with the perinuclear and central 
regions showing higher fluorescence than regions 
around the sarcolemma (Fig. 1, A). This may indi- 
cate a predilection for higher increases in Ca 2÷ 
concentration i  selected subcellular anatomic re- 
gions, or it could be due to contribution of out-of- 
focus fluorescence coming from different optical 
planes. 
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Fig. 1. Increase in intracellular Ca 2+ induced by a hyperkalemic solution in cardiac cells. Ventricular 
myocytes, loaded with the CaZ+-sensitive fluorescent probe, Fluo-3, were imaged by epifluorescent digital 
imaging. A, A series of four images obtained before (0 seconds) and 10, 15 and 25 seconds after aising the 
extracellular concentration of K + to 16 mmol/L. Horizontal bar corresponds to 20 ~m. Vertical bar 
represents he Fluo-3 fluorescence displayed in pseudocolors with a continuous rainbow pattern. B, Fluo-3 
fluorescence b fore (0 seconds; open circles) and 35 seconds after addition of K + (closed circles) recorded 
from ventricular myocytes obtained from 13 hearts. An estimate of the average change in intracellular Ca 2+ 
concentration is given in the text. 
To obtain a more precise spatial resolution of 
changes in intracellular Ca 2+, we used laser scan- 
ning confocal microscopy to record fluorescence 
from a single optical plane, thus effectively removing 
contributions of out-of-focus fluorescence. In 16 
myocytes, intracellular Ca 2+ concentration was ho- 
mogeneous before exposure (estimated average 
concentration 121 _+ 15 nmol/L) and increased by a 
factor of 3.5 (to an estimated concentration f425 _+ 
40 nmol/L) after exposure of a cardiac cell to a 16 
mmol/L concentration of K + (Fig. 2, A). The eleva- 
tion in intracellular Ca 2+ concentration was not 
uniform, with localized regions of higher concentra- 
tion surrounded by areas of lower concentration 
(Fig. 2, A). Spatial analysis did not reveal a predi- 
lection for higher increases in fluorescence in the 
central region of the cell versus the perisarcolemmal 
area. In several myocytes, temporal analysis re- 
vealed an oscillatory pattern in the elevation of 
fluorescence (not illustrated). Thus scanning laser 
confocal microscopy confirms that changes in fluo- 
rescence induced by high K+-containing solutions 
were related to nonhomogeneous elevation in intra- 
cellular Ca 2+ concentration. 
Omission of extracellular Ca 2+ does not prevent 
hyperkalemic solutions from inducing intracellular 
Ca 2+ loading. Extracellular Ca 2+ has been omitted 
from some eardioplegic solutions (e.g., Bretschnei- 
der solution) with the expectation that this modifi- 
cation will prevent intracellular Ca 2+ loading. 1 To 
determine whether removal of extracellular Ca 2+ 
prevents changes in intracellular Ca 2+ concentra- 
tion, we exposed single myocytes to hyperkalemic, 
nominally Ca2+-free solutions. As depicted in Fig. 3, 
a 16 mmol/L concentration of K + induced an in- 
crease in intracellular Ca 2÷ concentration, under 
this condition. When cardiac myocytes were exposed 
to hyperkalemic nominally Ca2÷-free solutions, in- 
tracellular Ca 2÷ concentration, was increased on 
average to 396 _+ 50 nmol/L (n = 12), a concentra- 
tion not significantly different from that obtained in 
solutions containing a 1.8 mmol/L concentration of
extracellular Ca 2-. Thus omission of extracellular 
Ca 2÷ from hyperkalemic solutions apparently does 
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Fig. 2. Spatiotemporal distribution of intracellular Ca 2+ revealed by laser confocal microscopy. Laser 
confocal microscopy was used to optically section a binucleated, Fluo-3 loaded, cardiomyocyte. A, Series 
of confocal images obtained before (0 seconds) and 11, 35, and 121 seconds after raising the extracellular 
concentration f K + to 16 mmol/L. At time 0 seconds, the baseline cytosolic fluorescence of the myocyte 
was low. At time 11 seconds, a nonhomogeneous increase in fluorescence occurred. At time 35 seconds, 
fluorescence continued to increase, making more evident he nonuniform pattern of Ca 2+ elevation. At 
time 121 seconds, fluorescence decreased from its peak level but remained above baseline. Note that at all 
time points the fluorescence of the nuclei was higher than that of the cytosol. Horizontal bar represents 20 
/~m. B, Time course of changes in the average Fluo-3 fluorescence induced by raising the concentration f
K + in the myoeyte depicted in A. Intracellular Ca 2+ concentration i creased from an estimated 156 nmol/L 
(at 0 seconds) to 410 nmol/L (at 35 seconds) and 249 nmol/L (at 121 seconds). 
not prevent elevation in intracellular Ca 2+ concen- 
tration. 
Extracellular Mg z+ does not prevent hyperkale- 
mic solutions from increasing intracellular Ca 2+. 
Although it has been suggested that ddition of a 
16 mmol/L concentration of Mg 2+ to cardioplegic 
solutions has a protective ffect on the myocardi- 
urn, 12 it is not known whether elevating extracel- 
lular Mg 2+ prevents changes in intracellular Ca 2+ 
induced by hyperkalemic solutions. Exposure of 
cardiac cells to solutions containing 16 mmol/L 
concentrations of K + and Mg 2+ induced an in- 
crease in intracellular Ca 2+ concentration (Fig. 4, 
A). Despite the presence of Mg 2+, 16 mmol/L, 
elevation in intracellular Ca 2+ concentration was 
sustained (Fig. 4, B) and occasionally fluctuated, 
reflecting oscillations in intracellular Ca 2+ con- 
centration (Fig. 4, B). These oscillations may 
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16mM K + 
nominally Ca 2+ free 
0 15 30 45 sec 
Fig. 3. Excluding extracellular Ca 2+ does not prevent intracellular Ca 2+ increase. A series of four epiftuores- 
cent images recorded from a ventricular myocyte incubated in nominally free C  2+solution and exposed to K + 
in a concentration f 16 mmol/L shows a time-dependent increase in Fluo-3 fluorescence from a low resting 
level (0 seconds) before addition of K + to higher levels (at 15, 30, 45 seconds) after addition of K +. Horizontal 
bar corresponds to 25/~m. Vertical bar represents he Fluo-3 fluorescence displayed in pseudocolors. 
reflect continuous Ca 2+ release from and re- 
uptake into intracellular stores. In eight myocytes 
(Fig. 4, C), the average elevation of intracellular 
Ca 2+ concentration was to 463 + 28 nmol/L, a 
value not significantly different from that obtained 
in low extracellular Mg 2+. Thus supplementation 
of hyperkalemic solutions with Mg 2+, 16 retool/L, 
a concentration used in the St. Thomas' Hospital 
II cardioplegic solution, does not prevent the 
increase in intracellular Ca 2+ concentration in- 
duced by a hyperkalemic challenge in ventricular 
myocytes. 
Potassium channel opening drugs prevent hy- 
perkalemic solutions from inducing an increase in 
intracellular Ca 2+. Potassium channel opening 
drugs, such as aprikalim and nicorandil, protect he 
myocardium from ischemic insults and modulate 
intracellular Ca a÷ concentration i smooth muscle 
cells. 22-25 Cardiomyocytes were pretreated with 
aprikalim (a thioformamide) or nicorandil (a nico- 
tinamide) before being exposed to the 16 mmol/L 
K + solution. Aprikalim (40 ~mol/L) or nicorandil 
(300/xmol/L) prevented K + 16 mmol/L from induc- 
ing an increase in intracellular Ca 2+ concentration 
in all 21 myocytes o tested (Fig. 5). The intracellu- 
lar Ca 2+ concentrations after addition of K + 16 
mmol/Lwere 115 _+ 7 nmol/L (n = 10) and 135 _+ 4 
nmol/L (n = 11) in aprikalim- and nieorandil- 
treated myocytes, respectively. Thus potassium 
channel opening drugs protect myocytes from hy- 
perkalemia-induced intracellular Ca 2+ loading. 
Glyburide antagonizes the ability of a potassium 
channel opening drug to prevent hyperkalemia- 
induced elevation in intracellular Ca 2+. Potassium 
channel opening drugs activate myocardial ATP- 
sensitive K + channels. 26, 27 Cardiac cells were 
therefore treated with glyburide (6 tzmol/L), a 
selective blocker of ATP-dependent K + chan- 
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Fig. 4. Supplementing hyperkalernic solutions with MgC12, 16 mmol/L, does not prevent intracellular 
Ca 2÷ increase. A, A series of four epifluorescent images obtained from a single cardiac myocyte b fore (0 
seconds) and 8, 16, and 24 seconds after exposure to 16 mmol/L doses of KC1 and MgC12. Horizontal bar 
corresponds to 15/xm. Vertical bar represents he Fluo-3 fluorescence displayed in pseudocolors. B, Time 
course of relative changes in Fluo-3 fluorescence induced by 16 mmol/L doses of KC1 and MgC12 in the cell 
depicted in A. C, Average fluorescence atrest and 35 seconds after exposure of eight ventricular myocytes 
to 16 mmol/L doses of KC1 and MgC12. Star corresponds to p < 0.01. An estimate of changes in the 
intracellular Ca 2÷ concentration is given in the text. 
nels.28, 29 In glyburide-treated myocytes, aprikalim 
was unable to prevent an elevation in intracellular 
Ca 2+ induced by K ÷ 16 mmol/L (Fig. 6). In 
glyburide- and aprikal im-treated myocytes, intra- 
cellular Ca 2+ concentration was 150 _+ 6 nmol/L 
before and 422 + 49 nmol/L after K ÷ 16 mmol/L 
was added (n = 9). These results suggest that 
potassium channel openers prevent high K + from 
increasing intracellular Ca 2+ through a glyburide- 
sensitive mechanism. 
Discussion 
The present study demonstrates that hyperkalemic 
solutions elevate intracellular Ca ~+ concentration i
isolated ventricular myocytes. These results extend 
previously obtained findings from multieellular heart 
preparations and cardiac ell suspensions 9' 10 and pro- 
vide direct evidence, at the single cell evel, that 
hyperkalemic solutions such as the one used in cardio- 
plegia can increase intracellular Ca 2+ concentration. 
An increase in intracellular Ca 2+ concentration could 
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Fig. 5. Supplementing hyperkalemic solutions with potassium channel openers prevents intracellular Ca 2+ 
increase. A, A series of epifluorescent images obtained from a single Fluo-3AM-loaded myocyte pretreated 
for 10 minutes with aprikalim and imaged before (0 seconds) and 15, 30, and 45 seconds after exposure to 
K +, 16 retool/L, in the continuous presence of aprikalim. B, Fluorescence r corded from 10 myocytes under 
three conditions. Left, open circles: baseline; right, open circles: in aprikalim (40/xmol/L); closed circles: in 
aprikalim and K ÷, 16 mmol/L. C, A series of epifluorescent images of a single Fluo-3AM-loaded myocyte 
pretreated for 10 minutes with nicorandil and imaged before (0 seconds) and 15, 30, and 45 seconds after 
exposure to 16 mmol/L K ÷, in the continuous presence of nicorandil. D, Fluorescence r corded from 11 
myocytes under three conditions. Left, open circles: baseline; right, open circles: in nicorandil (300/zmol/L); 
closed circles: in nicorandil and 16 mmol/L K +. An estimate of the changes in intracellular Ca 2+ 
concentration is given in the text. Horizontal bar corresponds to 10/xm in A and C. 
potentially lead to cellular dysfunction and con- 
tribute to myocardial damage, as previously de- 
scribed in various pathophysiologic onditions 
associated with a hyperkalemic challenge, such as 
cardioplegic arrest. 5
The observed elevation in cytosolic Ca 2+ was 
modest and did not lead to apparent shortening of 
the hyperkalemia-challenged cardiomyocyte. Yet 
moderate levation of cytosolic Ca z+ has been re- 
lated to signaling information independent of con- 
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Fig. 6. A selective inhibitor of ATP-sensitive K+ channels antagonizes the ability of a potassium channel 
opener to prevent hyperkalemia-induced intracellular Ca 2+ increase. A, A serie of four epifluorescent 
images obtained from a myocyte pretreated with glyburide plus aprikalim before (0 seconds) and 45, 90, 
180 seconds after addition exposure to K +, 16 mmol/L. B, Summary graph depicts Fluo-3 fluorescence 
recorded from nine myocytes. Circles correspond to fluorescence r corded in individual myocytes under 
three different conditions. Left, open circles: glyburide (6/xmol/L); right, open circles: glyburide (6/xmol/L) 
plus aprikalim (40/zmol/L); closed circles: glyburide (6/xmol/L) plus aprikalim (40/xmol/L) and K + (16 
mmol/L). An estimate of the changes in intracellular Ca 2+ concentration is given in the text. 
traction. 3° Because during cardioplegia the myocar- 
dium is under conditions of global ischemia with a 
lower production of ATP when compared with 
normal conditions, a modest elevation in intracellu- 
lar Ca 2+ could represent an additional load on the 
energy-dependent Ca2+-homeostatic mechanisms 
and could predispose cardiac cells to reperfusion 
injury and diastolic dysfunction. 4' 10 
The mechanism responsible for the hyperkale- 
mia-induced increase in intracellular Ca 2÷ concen- 
tration is most likely related to membrane depolar- 
ization, 2° because high K+-containing solutions 
depolarize by at least -30  mV the cell membrane of 
ventricular myocytes. 31 Membrane depolarization 
promotes Ca 2+ influx through voltage-dependent 
Ca 2+ channels. Ca 2+ influx, in turn, induces release 
of Ca 2+ from intracellular stores. 32 Additional 
membrane potential-sensitive processes that regu- 
late intracellular Ca 2+ homeostasis may also partic- 
ipate in the hyperkalemia-induced increase in intra- 
cellular Ca2+y 
Ca 2+ has been omitted from cardioplegic solu- 
tions to limit Ca 2+ overload during surgical isch- 
emia. 34 However, our results, with nominally Ca z+- 
free solutions indicate that omission of Ca 2+ from a 
hyperkalemic solution, as practiced with "acalce- 
mic" cardioplegia, does not necessarily prevent in- 
tracellular increase of Ca 2+. This finding may sug- 
gest that in nominally Ca2+-free solutions a 
sufficient concentration of extracellular Ca 2+ still 
remains in the extracellular space and could enter 
during membrane depolarization to trigger release 
of Ca 2+ from intracellular stores, leading to increase 
in intracellular Ca 2+ concentration. Indeed, the 
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peak value of Ca 2÷ current at a given membrane 
potential is dependent on the reversal of Ca 2+ 
potential which, on the basis of the Nernst equation, 
will not dramatically change ven after reduction of 
extracellular Ca 2+ to a value 10 to 20 times lower 
than control external Ca 2+ concentrations. Contam- 
ination of such magnitude may be present in "acal- 
cemic" solutions. In compromised myocytes, eleva- 
tion in intracellular Ca 2÷ concentration has been 
ascribed to mechanisms independent of Ca 2÷ influx 
through Ca 2+ channels. 35Further studies are re- 
quired to elucidate the source of Ca 2÷ leading to 
Ca 2÷ loading. That exposure of the heart to "acal- 
cemic" solutions did not prevent Ca 2+ loading is 
consistent with the clinical evidence showing that 
"acalcemic" ardioplegic solutions are not necessar- 
ily more protective than conventional cardioplegic 
solutions. 36 
In the myocardium, Mg 2÷ has been shown to act 
as a physiologic Ca 2÷ antagonist and is required as a 
cofactor to nucleotides for energy transfer eaction 
and transport processes. 37High concentrations of
Mg 2÷ in hyperkalemic cardioplegic solutions may 
have a beneficial effect by (1) antagonizing the 
unwanted effects of elevated intracellular Ca2+, 9' 38 
(2) reducing the leakage of myocardial enzymes, and 
(3) preventing ATP depletion. The present study 
shows that adding a 16 mmol/L concentration of
Mg 2+ to high K + solutions did not prevent he 
increase in intracellular Ca 2+. This finding does not 
necessarily rule out a protective ffect of Mg 2÷ on 
the myocardium during cardioplegic arrest indepen- 
dently from an increase in intracellular Ca 2÷ con- 
centration. 13
The major finding of the present study is that 
potassium channel opening drugs effectively prevent 
high K ÷ solutions (16 mmol/L) from increasing 
intracellular Ca 2+ concentration i cardiac cells. 
The precise mechanism ofaction of potassium chan- 
nel openers responsible for this effect is not known. 
Possible mechanisms could relate to the ability of a 
potassium channel opener to keep the membrane 
potential at a more negative value when the extra- 
cellular K + concentration is less than 20 mmol/L. 23 
It has been reported that a potassium channel 
opener shifts the resting membrane potential of 
muscle cells by approximately 15mV to the negative 
direction at an extracellular concentration of K ÷ 
close to 16 mmol/LY Previously, we have demon- 
strated, at the whole cell and single channel level 
using the patch-clamp technique, that the potassium 
channel opening drugs used in this study, aprikalim 
and nicorandil, selectively activate ATP-sensitive 
K + channels in cardiac cells. 26'27'39 In vascular 
smooth muscle, K ÷ channel openers appear to 
prevent hyperkalemic solution-induced increase in 
intracellular Ca 2÷ by keeping the membrane poten- 
tial above the gating level of voltage-sensitive Ca2÷ 
channels and preventing Ca 2+ entry, a3 In view of the 
voltage-dependence of cardiac Ca 2÷ channels, a 
similar mechanism could be involved in underlying 
the reduction in Ca 2÷ influx during depolarization. 
At higher extracellular K ÷ concentrations (above 20 
mmol/L), potassium channel openers will still open 
K + channels; yet this effect will not translate into a 
change in the value of the resting membrane poten- 
tial, since net K + efftux under these conditions is 
much less pronounced. 23 Indeed, at an extracellular 
K ÷ concentration f 32 mmol/L, we have found no 
protective ffect of potassium channel openers on 
hyperkalemia-induced Ca2÷ loading in cardiac 
cells, g° Also, potassium channel openers have been 
proposed to regulate intracellular Ca 2÷ handling in 
addition to their effect on the cellular mem- 
brane.22, 3 Thus several mechanism(s) may underlie 
the effect of potassium channel openers on prevent- 
ing hyperkalemia-induced Ca a+ loading in cardiac 
cells. 
In various models of ischemia, opening of ATP- 
sensitive K + channels has been associated with 
cardioprotection. 25'41'42 In whole heart prepara- 
tions and intact animals, aprikalim protected the 
myocardium from ischemic damage through a gly- 
buride-sensitive mechanism. 2s'42'43 The present 
finding, that glyburide, a selective blocker of ATP- 
sensitive K ÷ channels, 28' 29 prevented the protective 
effect of aprikalim on hyperkalemia-induced intra- 
cellular Ca 2+ increase suggests that opening of 
ATP-sensitive K + channels may play a role in 
protecting cardiac ells from Ca 2+ loading. 
Recently, it has been shown that potassium chan- 
nel openers accelerate the recovery of myocardial 
function and preserve intracellular adenosine 
triphosphate content and mitochondrial structure 
after global surgical ischemia. 43-4s Under these con- 
ditions, potassium channel openers may be superior 
to calcium channel blockers that do not affect post- 
ischemic recovery. 46However, the clinical use of 
potassium channel openers should be considered 
with caution because of the systemic effects, such as 
vasodilation, and the limited clinical experience with 
this novel family of therapeutics. 47 Although im- 
proved tissue selectivity of this class of compounds i  
an important prerequisite for the wide clinical use of 
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potassium channel openers, the experimental evi- 
dence that these agents could be beneficial as a 
supplement to hyperkalemic cardioplegic solutions 
during cardiopulmonary bypass are encourag- 
ing. 43-45 The findings presented herein further sup- 
port such a notion because they indicate that in 
single cardiac cells, potassium channel openers 
could alleviate potentially deleterious increases in 
intracel lu lar  Ca 2+ concentration associated with hy- 
perkalemic hallenges. 
We gratefully acknowledge the technical assistance of 
James E. Tarara and Teresa J. Halsey with the epifluo- 
rescent imaging system and the assistance of Dr. Ray 
Ghanbari with confocal microscopy. 
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